Dr Yu speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PRODIGE 24 study which concerned patients with resected pancreatic ductal adenocarcinomas.

He describes the clear-cut result of this study and thus his opinion that the standard of change should change on these patients, particularly for those patients who can tolerate a more intensive chemotherapy regimen.

He then discusses the PREOPANC study which looks at chemotherapy before and after, or only after surgery.